Napo Therapeutics is focused on expanding access to crofelemers in Europe for the treatment of patients with rare diseases – starting with short bowel syndrome (SBS)
For SBS, Napo Therapeutics was granted Orphan Drug Designation for crofelemer by the European Medicines Agency, and Jaguar Health was granted Orphan Drug Designation for crofelemer by the FDA
SAN FRANCISCO, CA and MILAN, ITALY/ACCESSWIRE/January 24, 2022/ Jaguar Health (NASDAQ: JAGX) and Napo Therapeutics SpA, an Italian company established by Jaguar Health in Italy, today announced the appointment of Martire Particco, MD, a physician with over 30 years of experience in the European pharmaceutical industry and in clinical practice, as Chief Medical Officer of Napo Therapeutics. Dr. Particco has extensive experience in the field of rare diseases, having been involved in the clinical development and launch of Pfizer’s pulmonary hypertension indication for sildenafil and the clinical development of the ligneous conjunctivitis indication of Kedrion Biopharma for plasminogen, with direct experience with patients and experts treating these rare pathologies.
“We are delighted to have Dr. Particco join our team in this key leadership role in Milan,” said Massimo Mineo, CEO of Napo Therapeutics. “Dr. Particco brings extensive experience in drug development, managing clinical trials in and outside Europe, and developing and executing successful pre-launch and launch plans for drugs for diseases rare – which will support our main objective. on access to crofelemer in Europe for our two initial and significant rare/orphan disease indications: short bowel syndrome with intestinal failure (SBS-IF) and congenital diarrheal disorders (CDD).”
From 2016 to 2021, Dr. Particco served as Vice President, Head of Medical Affairs for Europe for Shionogi Europe, the subsidiary of a leading Japanese pharmaceutical company with global sales of $2.5 billion. euros. Prior to this role, Dr. Particco was Shionogi Europe’s Country Medical Director for Italy and in 2013 held the position of Country Medical Director for Italy for UCB Italy, a leading European biopharmaceutical company. plan with a worldwide turnover of 4.6 billion euros. He was also director of global pharmacovigilance, medical and clinical affairs for the Italian company Kedrion Biopharma and national medical director for Italy of Warner Chilcott, the Italian subsidiary of an American pharmaceutical company which is now part of Abbvie. Dr. Particco worked at Pfizer/Wyeth from 1999 to 2010, as Senior Medical Advisor for Biotechnology from 2007 to 2010, and previously as Medical Advisor and Training Specialist at Pfizer. From 1990 to 1999, Dr. Particco worked as an obstetrician-gynecologist in Rome, both in private practice and in public health. He obtained his degree in medicine and surgery and his specialist degree in gynecology and obstetrics from La Sapienza University in Rome.
“I am very pleased to have the opportunity to lead Napo Therapeutics’ clinical programs to support the European market approval of a first-in-class herbal medicine like crofelemer, starting with our important target indications of SBS-IF and CDD,” said Dr. Particco.
About Jaguar Health, Inc., Jaguar Animal Health, Napo Pharmaceuticals, Inc. and Napo Therapeutics SpA
Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing novel herbal, non-opioid, and sustainably-derived prescription medicines for people and animals suffering from gastrointestinal distress, particularly chronic and debilitating diarrhoea. Jaguar Animal Health is a trading name of Jaguar Health. Jaguar Health’s wholly owned subsidiary, Napo Pharmaceuticals, Inc., is focused on the development and commercialization of proprietary plant-based human gastrointestinal pharmaceuticals from plants responsibly harvested from rainforest areas. Jaguar Health is the majority shareholder of Napo Therapeutics SpA, an Italian company established by Jaguar Health in Milan, Italy in 2021, which is focused on expanding access to crofelemers in Europe.
For more information about Jaguar Health, visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit www.napotherapeutics.com.
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not taken into account, there is a risk that patients with infectious etiologies will not receive appropriate treatment and that their disease will worsen. In clinical studies, the most common adverse reactions occurring at a higher rate than placebo were upper respiratory tract infections (5.7%), bronchitis (3.9%), cough (3.5% ), flatulence (3.1%) and increased bilirubin (3.1%). ).
See complete prescribing information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (herbal) medicine extracted and purified from the sap of the red bark of the medicinal plant. Croton lechleri tree in the Amazon rainforest. Napo has implemented a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Certain statements contained in this press release constitute “forward-looking statements”. These include statements regarding the expectation that Dr. Particco’s experience will support Napo Therapeutics’ focus on providing access to crofelemer in Europe for SBS-IF and CDD. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “expect”, “plan”, “aim”, “anticipate”, ” could”, “intend”, “target”, “project”, “consider”, “believe”, “estimate”, “predict”, “potential”, or “continue” or the negative form of these terms or other similar expressions. The forward-looking statements contained in this release are only predictions. Jaguar Health has based these forward-looking statements largely on its current expectations and projections regarding future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar Health’s control. Except as required by applicable law, Jaguar Health does not intend to update or publicly revise statements forward-looking statements contained herein, whether as a result of new information, future events, changed circumstances or otherwise.
Jaguar Health, Inc.
Jaguar – JAGX
THE SOURCE: Jaguar Health, Inc.
See the source version on accesswire.com: